The American medical system's emphasis on 15-minute visits and efficiency incentivizes prescribing medication to treat symptoms rather than unraveling root causes. This approach aims to "polish the hood when there's a problem in the engine."

By offering deep discounts exclusively through select telehealth platforms, drugmakers create a powerful sales channel that may incentivize providers to preferentially prescribe their products. This arrangement raises ethical concerns that financial incentives could override independent medical judgment, potentially compromising patient care.

The number of Americans recommended for statins ballooned from 13 million to 56 million due to progressively lowered cholesterol thresholds. The expert committees setting these guidelines often had members with financial ties to drug makers, creating a conflict of interest.

Dr. Unwin's career pivoted after a patient revealed she normalized her blood sugar by cutting carbs—a method she learned from a 40,000-strong online community. This highlights the power of patient-led research and community knowledge in healthcare.

The conviction of an ADHD startup founder for over-prescribing Adderall illustrates the danger of optimizing healthcare for conversions. It proves that a doctor's assessment and incentive for quality care is a critical patient safety feature, not a bug to be removed by tech.

The medical establishment's fear of lawsuits over acute events (like a fatal low blood sugar incident) leads to diabetes management strategies that prevent short-term disasters but allow long-term, debilitating complications like blindness. This incentive misalignment suppresses simpler, more effective dietary solutions that could improve quality of life.

Pharma companies now partner with telehealth providers to offer coupons that reduce the cost of the physician consultation itself. This marketing tactic incentivizes patients to seek a prescription for a specific drug, raising questions about overprescribing and conflicts of interest.

Dr. Smith argues that while drugs are essential for acute emergencies like heart attacks or broken bones, they are ill-suited for chronic problems. For long-term issues, focusing on root causes is more effective than continuous symptom management with medication.

Oncologists typically initiate metformin for drug-induced hyperglycemia but are hesitant to manage more complex regimens. They prefer collaborating with endocrinologists who can navigate different drugs, dosages, and interactions, especially for complex oncology patients where frequent follow-up is needed.